Announcement PDF Annual Report 2025 Actinogen is advancing a revolutionary oral therapeutic, Xanamem® , through pivotal trials to transform treatment for Alzheimer’s disease and major depressive disorder. Our vision is to improve lives by targeting brain cortisol with precision and innovation. ® Xanamem is a registered trademark of Actinogen Medical Limited Contents Who we are IFC Highlights 2 The Xanamem pipeline 3 MDD trial results 4 XanaMIA phase 2b/3 Alzheimer’s disease trial 6 The Alzheimer’s market 7 Chair’s letter 8 Chief Executive Officer’s letter 10 Vision and strategy 12 Operating & financial review 14 Board of directors 24 Executive leadership team 26 Directors’ report 28 Remuneration report (Audited) 31 Auditor’s independence declaration 44 Financial report 45 Directors’ declaration 70 Independent auditor’s report 71 Shareholder information 75 Corporate directory 78 Disclaimer This annual report may contain certain "forward-looking statements" that are not historical facts; are based on subjective estimates, assumptions and qualifications; and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements should be considered “at-risk statements” - not to be relied upon as they are subject to known and unknown risks, uncertainties and other factors (such as significant business, economic and competitive uncertainties / contingencies and regulatory and clinical development risks, future outcomes and uncertainties) that may lead to actual results being materially different from any forward looking statement or the performance expressed or implied by such forward looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Actinogen Medical does not undertake any obligation to revise such statements to reflect events or any change in circumstances arising after the date hereof, or to reflect the occurrence of or non-occurrence of any future events. Past performance is not a reliable indicator of future performance. Actinogen Medical does not make any guarantee, representation or warranty as to the likelihood of achievement or reasonableness of any forward-looking statements and there can be no assurance or guarantee that any forward-looking statements will be realised. Annual Financial Report 1 Highlights Planning for commercial readiness 1 MDD = major depressive disorder 2 USAN = A United States Adopted Name (USAN) is a unique nonproprietary name assigned to a medication marketed in the United States 3 Unless stated otherwise, all financial data is in Australian dollars Pivotal XanaMIA phase 2b/3 AD clinical trial passes 100th participant milestone. Interim analysis scheduled for Jan 2026; final results Q4 2026 Conducted successful Type C regulatory meeting on MDD1 with the US FDA to reach common understanding of path to marketing approval of Xanamem for MDD Appointed experienced inaugural Chief Commercial Officer (CCO), Andy Udell, based in the USA to manage commercialization activities Delivered another in series of ’plain English’ Clinical Trials Science Forum (CTSF) neuroscience webinars titled: The critical importance of preparing for commercialization World Health Organization granted new and unique International Nonproprietary Name ‘emestedastat’ to Xanamem and also accepted in US as USAN2 Published an academic manuscript in peer- reviewed journal, Clinical Pharmacology in Drug Development detailing the multiple trials supporting the utility of Xanamem 10mg Completed an $11.1m capital- raising, received a $9.0 million R&D tax incentive rebate & established a $13.8m non- dilutive R&D tax incentive funding facility. Funding secured to mid-late CY 20263 Initiated clinical pharmacokinetic trial and other ancillary studies. Commenced preparation for an ‘open-label’ extension trial beginning Q1 2026 to allow XanaMIA trial participants to continue with active Xanamem therapy Announced positive depression results from XanaCIDD phase 2a trial supporting Xanamem’s cortisol control mechanism & confirming clinical activity of 10mg daily dose Completed production of 15kg scale-up batch of drug substance from contract manufacturer, Asymchem, to be manufactured in the US into Xanamem tablets Attended & presented at significant international conferences and conducted meetings at industry gatherings to enable evaluation of potential value-add regional and global business development opportunities Strengthened engagement and understanding among external stakeholders through a high-quality, two-minute mechanism-of- action animation View here Actinogen Medical Limited 2 The Xanamem pipeline Progressing Xanamem in Alzheimer’s disease, major depressive disorder and other neurological indications Alzheimer’s disease MDD Fragile X syndrome Indication Preclinical Phase 1 Phase 2 Phase 3 Paused after phase 2a pending phase 2b/3 trial funding Paused prior to phase 2 Phase 2b/3 interim analysis Jan 2026, final results late 2026 Open INDs Frontotemporal dementia Lewy-body dementia Parkinson’s disease Anxiety disorders MDD: Major depressive disorder Potential next indications Annual Financial Report 3 MADRS depression scores favour Xanamem at Week 6 & 10 in patients also taking SSRI drugs (n = 76) Patient Global Impression – Severity scores favour Xanamem from Week 2 in patients also taking SSRI drugs (n = 75) MADRS LS mean change from baseline (± SE) ON TREATMENT -12 0 Baseline Week 2 Xanamem (n=37) Placebto (n=39) Week 4 Week 6 Week 10 PT -2 -4 -6 -8 -10 FOLLOW UP PT 4.2-point difference Cohen’s d = 0.64 p = 0.03 EOT 2.6-point difference Cohen’s d = 0.38 p = 0.15 BETTER BETTER -1.4 -1.6 0 -0.4 -0.2 -0.6 -0.8 -1 -1.2 PT 0.59-point difference Cohen’s d = 0.62 EOT 0.41-point difference Cohen’s d = 0.43 PGI-S LS mean change from baseline (± SE) Xanamem (n=36) Placebo (n=39) Baseline Week 2 Week 4 Week 6 Week 10 PT ON TREATMENT FOLLOW UP Abbreviations: MADRS = Montgomery-Åsberg Depression Rating Scale; EOT: End of Treatment; PT: Post Treatment; SSRI = selective serotonin reuptake inhibitor; • A clinically meaningful improvement in depression symptoms, measured by the MADRS score, was seen after 6 weeks of therapy vs. placebo, and was then greater and statistically significant after four weeks of “blinded” post-treatment follow up • The placebo-subtracted treatment difference of 4.3 MADRS points is similar to that seen with currently approved anti-depressants • These data suggest that Xanamem could be beneficial as “add-on” therapy to SSRI drugs • Developing Xanamem in combination with SSRI drugs is a viable and pragmatic pathway to approval in major depressive disorder Further exploration of trial results showed encouraging activity for Xanamem when patients were also taking background Selective Serotonin Reuptake Inhibitor (SSRI) drugs – the commonest class of anti-depressant therapy in clinical use. MDD trial results XanaCIDD depression trial shows positive Xanamem activity on top of background SSRI therapy Actinogen Medical Limited 4 The XanaCIDD depression benefits show that controlling cortisol levels in key areas of the brain has a clinically important effect, increasing our confidence in positive outcomes for trials in depression, Alzheimer’s disease and other diseases where cortisol plays a role. Analysis of patients also taking SSRI drugs suggests that Xanamem’s benefit on depressive symptoms may be greater in this patient population and points us toward studying this combination in future clinical trials. Dr Dana C Hilt Actinogen’s Chief Medical Officer Annual Financial Report 5 XanaMIA phase 2b/3 Alzheimer’s disease trial - rapidly approaching major milestones NIA-AA=National Institute of Aging - Alzheimer’s Association; CDR-SB Clinical Dementia Rating Scale – Sum of Boxes Key Inclusion Criteria •Blood pTau biomarker positive •Mild-moderate Alzheimer’s by NIA‑AA criteria Primary Endpoint •CDR-SB (functional and cognitive measure) @36 weeks •Also measured at 12 and 24 weeks Key Secondary Endpoints •Cognitive Test Battery (7 cognitive measures well‑validated in the Alzheimer’s field) •Amsterdam Activity of Daily Living (functional measure) Implementation •Enrolment at 15 Australian & 20 US sites •Interim analysis January 2026 (efficacy futility & safety) •High quality endpoint monitoring 2026 2027 and beyond Interim Analysis January 2026 Final Results Late 2026 Q3 2025 More than 50% enrolled Q4 2025 Target full enrolment Q1 2026 Open label extension commences Key trial criteria 10mg Xanamem vs Placebo (n=220) Actinogen Medical Limited 6 The Alzheimer’s market Large and unsatisfied Alzheimer’s market Growing Alzheimer’s disease market - U.S. 2025 2025 2060 (Est.) 13.8M 7.2M 64% 38% 32% 31% 18% 12% 8% 13% $384B $1T 2050 (Est.) Number of patients (65+ years old) Cost to treat (USD) Above and right: Spherix Global Insights: Market Dynamix Early Alzheimer’s Disease (US) Q2 2025 (n=101) and Custom Quantitative Analysis (US) July/August 2025 (n=91) Sources: U.S. burden of Alzheimer’s disease, related dementias to double by 2060 | CDC Online Newsroom | CDC, US Alzheimer’s Prevalence Surpasses 7 Million Source: The Cost of Dementia in 2025 - April 23, 2025 - USC Schaeffer Advantages of Xanamem (Unaided) % of respondents Oral Safety profile Novel MOA Efficacy No ARIA No DDI Tolerability profile Other Positive reaction to Xanamem’s potential advantages per clinician feedback of neurologists agree there is a high unmet need for DMTs for early AD 91% of neurologists expect their approach to treating early AD will change over the next 5 years as novel DMTs launch 86% DMTs: Disease modifying therapies ARIA: Amyloid-related imaging abnormalities “ Oral agent with distinctive mechanism of action, no safety concern.” “ More efficacious, oral, no concern for ARIA, can be used in more advanced AD.” “ It appears to be quite safe. There is little work to be done on the part of the clinician or the patient (dosing, labs, titration, etc.)” Annual Financial Report 7 Chair’s letter Dear Shareholder, I am pleased to present to you the Actinogen Medical Annual Report for the financial year ended 30 June 2025 reflecting on a period of significant progress in a dynamic global environment. Actinogen has continued to make excellent progress in the fulfillment of its business priorities and strategic objectives in the 2025 financial year. The past year has been marked by a rebound of interest in small-cap biotechnology, particularly those advancing into later stages of clinical development. In both the United States and Australia, investor sentiment has gradually improved, buoyed by more favourable economic conditions and renewed appetite for innovation in healthcare. This has led to a general rotation of capital into high-quality small- and mid-cap biotechs, especially those with promising phase 2/3 assets. Actinogen is in exactly that “sweet spot” with its Xanamem pivotal trial program. Against this backdrop, Actinogen has delivered a year of meaningful progress. Our novel, small molecule asset, Xanamem, advanced in two major indications—Alzheimer’s disease and major depressive disorder—both of which represent areas of significant unmet medical need. For now, Alzheimer’s disease is the primary focus for company resources given the immense potential value a new, oral therapy for this disease represents. Addressing a significant global health need Alzheimer’s disease remains one of the most pressing healthcare challenges of our time. With over 55 million people affected globally and no cure currently available, the demand for effective therapies is only growing. Recent drug approvals for anti-amyloid infusion therapies, that have only modest benefit, underscore the opportunity for next-generation therapies such as oral Xanamem. Actinogen’s focus on modifying the progression of Alzheimer’s by controlling brain cortisol positions us as unique in this space. There is no other similar drug in development for CNS diseases to our knowledge. We are proud to be contributing to a global effort to slow, halt, or even reverse the functional and cognitive decline associated with this devastating condition. Executive leadership I would also like to commend the outstanding performance of our high-calibre senior leadership team, impeccably led by Dr. Steven Gourlay. Their strategic leadership, scientific knowledge and expertise, and unwavering commitment have been instrumental in driving the company’s progress. We also welcomed Mr Andrew (Andy) Udell to the team as Chief Commercial Officer. His commercial expertise adds valuable depth to our executive team as we complete later-stage clinical development and prepare the path to product launch. I also extend my appreciation to our wider executive team, dedicated employees, and key contractors. Their professionalism and dedication have been vital in maintaining a highly effective and efficient clinical development program and the corporate operations required of a publicly listed biotechnology company. Their collective efforts continue to drive Actinogen forward with purpose and momentum. Actinogen Medical Limited 8 Board, corporate governance and advisory boards Our Board remains committed to the highest standards of corporate governance and management oversight capability. During the year, we reviewed our governance practices and reassessed the Board skills matrix to identify areas for enhancement and future capability needs. We continue to evolve our governance framework to reflect the company’s growth and operational complexity. Our commitment to transparency and accountability remains strong, with all key corporate policies and governance materials available on our website. This framework supports the effective management and execution of both our long- term strategic vision and annual priorities. I would like to express my sincere appreciation to my fellow Board members for their valuable contributions and leadership throughout the year. Their strategic insight, governance leadership, and steadfast commitment have been instrumental in supporting Actinogen as we continue to navigate the complexities of late-stage clinical development. The Board also acknowledges the valuable insights and guidance provided by our scientific and medical advisory boards, which provide strategic guidance as we navigate clinical and regulatory pathways. Further details on the Actinogen corporate board, advisory boards and senior executive personnel can be found on the company’s website. Capital management We strengthened our financial position through a successful capital raise of $11.1 million, the completion of which was announced in October 2024, comprising an $8.1 million placement and a $3.0 million Share Purchase Plan. Subscribers also received listed options as part of the capital raising, so the company now has two series of options trading on the ASX. This provides flexibility for shareholders and potential capital for future growth if and when those options are exercised. In addition, we received a $9.0 million R&D tax incentive rebate in October 2024 for the 2024 financial year and recently secured access to up to A$13.8 million via a non‑dilutive loan funding facility secured against the company’s future Research and Development Tax Incentive (RDTI) rebates. Annual General Meeting This year’s Annual General Meeting will be held in person in Sydney on Wednesday 19 November 2025, and we look forward to engaging with shareholders on our progress and future plans. Details of the meeting time and Sydney location will be announced in due course. Outlook We enter the new financial year with optimism. The interim analysis of efficacy and safety of our pivotal XanaMIA AD trial, expected in January 2026, will be an important milestone. Assuming it is positive, it will provide valuable momentum for the clinical program and support ongoing engagement with potential partners and stakeholders. It will also mean that we will be even closer to final topline trial results expected late in 2026, which are keenly anticipated. In closing, I would like to sincerely thank you, our shareholders, for your continued support and confidence in Actinogen. Your backing enables us to pursue our work with focus and determination, and we are grateful for your ongoing engagement as we progress through this pivotal phase of development. We look forward to sharing further updates with you over the coming year as we continue working to deliver meaningful innovation for patients and value for shareholders. Dr Geoff Brooke Chair 25 August 2025 If you have any questions relating to your shareholding in Actinogen, please contact Automic at hello@automicgroup.com.au or on 1300 288 664 (within Australia) or +61 2 9698 5414 (outside Australia). Visit the Automic website https://investor. automic.com.au/#/home to register as an ACW shareholder or log in to your existing account. Annual Financial Report 9 Chief Executive Officer’s letter Dear Shareholder, Approaching key Xanamem pivotal trial results in Alzheimer’s disease. I am pleased to provide you with an update on Actinogen Medical’s progress over the past year. Since July 2024, we have made significant strides in advancing our clinical programs, strengthening our financial position, and preparing for commercialization of our lead asset, Xanamem. Clinical Development Milestones and Peer-Review Publications Our commitment to developing Xanamem as a novel therapy for Alzheimer’s disease (AD) continues to yield promising results. In June 2025, we reached a major milestone with the enrolment of the 100th participant in our XanaMIA phase 2b/3 AD trial. This achievement sets the stage for our interim analysis in January next year, which is expected to provide valuable insights into the efficacy and safety of Xanamem in this population. The interim analysis will be conducted by an Independent Data Monitoring Committee and look at available data for participants at 12, 24 and 36 weeks of treatment. Full enrolment of all 220 participants in the XanaMIA trial is expected by the time of the interim analysis, with topline, final results for 36 weeks of treatment expected in Q4 2026. A new “open label” extension trial to provide active Xanamem to all participants who complete the XanaMIA trial will start enrolment in Q1 of 2026. Earlier in the year, our Chief Medical Officer presented positive depression data from the XanaCIDD phase 2a trial at the American Psychiatric Association 2025 conference, reinforcing the therapeutic potential of Xanamem in major depressive disorder (MDD), AD and other brain diseases. The finding of clinical benefits on depressive symptoms confirms the clinical activity in the brain of the 10 mg dose of Xanamem – highly relevant to the XanaMIA trial where the same dose is used. The XanaCIDD data were discussed in our Type C meeting with the FDA in March 2025, where we clarified the regulatory pathway for Xanamem in MDD, laying the groundwork for future pivotal trials should the company’s focus shift away from AD as its lead indication. We continued to work towards peer-review of all our key trial results with the publication of a manuscript in the Clinical Pharmacology in Drug Development journal entitled “Clinical Pharmacology and Approach to Dose Selection of Emestedastat, a Novel Tissue Cortisol Synthesis Inhibitor for the Treatment of Central Nervous System Disease”. In addition, multiple academic posters were presented at scientific AD meetings. Actinogen Medical Limited 10 Commercialization Preparation We are actively preparing for the commercialization of Xanamem, which is likely to be in collaboration with one or more biopharmaceutical partners. In recognition of the importance of this work, in October last year we appointed Mr Andrew (Andy) Udell to the position of Chief Commercial Officer, based in Connecticut, USA. In January we announced the award of the generic or official chemical name for Xanamem of “emestedastat”, determined by the naming committee of the World Health Organization and later agreed to by a similar committee in the US. The new and unique suffix of “- stedastat” acknowledged Xanamem as the first-in-class inhibitor of its target cortisol production enzyme, 11β-HSD1. Our Clinical Trials Science Forum held in May 2025 focused on the marketing planning activities associated with the transition towards commercialization. Dana Hilt, CMO, and Andy Udell, CCO, with AD expert guest Associate Professor Michael Woodward, discussed the AD field and Xanamem’s position in it as we look beyond pure clinical development to market planning and execution, a critical future step in delivering value to patients and shareholders. Throughout the year Mr Udell and Dr Hilt have increasingly engaged with thought leaders in both AD and MDD to refine the product offering Xanamem will represent to prescribing physicians and their patients. This included advisory board meetings, one-on-one interactions and formal market research. Manufacturing During the year, our Head of Manufacturing, Ms Fujun Li, worked diligently to achieve several key milestones. The most important of these was the successful scale-up of production of the active pharmaceutical ingredient (API) of Xanamem to the 15 kg level. This API will be manufactured into our intended commercial tablet formulation in the US. Financial Strength and Funding Actinogen remains financially robust as a result of the successful execution of multiple funding initiatives throughout the year. At the end of June, our cash balance was $16.5 million, contributing to a cash runway beyond mid CY2026 in combination with our RDTI future income. We continue to explore funding from strategic partnerships and other non-dilutive funding sources to support our growth while preserving shareholder value. Strategic Engagements Actinogen’s visibility in the global biotech community has grown. We presented at the BIO International Partnering Conference in June 2025, engaging with potential collaborators and investors. Similarly, our presence at the Sachs Neuroscience conference in January 2025 provided opportunities to update and engage multiple large and mid- tier biopharmaceutical companies on our progress. These efforts are part of our broader strategy to attract synergistic strategic partners and position Actinogen as a leader in AD drug development. Looking Ahead The coming year will be pivotal. We anticipate interim results from our AD pivotal trial, further regulatory engagement with both the FDA and European Medicines Agency (EMA) on AD, and continued progress in our commercialization strategy. Our team remains focused on executing with excellence and transparency. I want to thank you—our shareholders—for your continued support and belief in our mission. Actinogen is entering a transformative phase, and your partnership is vital as we work to bring Xanamem to patients in need. Warm regards, Dr Steven Gourlay CEO & Managing Director 25 August 2025 If you have any questions relating to your shareholding in Actinogen, please contact Automic at hello@automicgroup.com.au or on 1300 288 664 (within Australia) or +61 2 9698 5414 (outside Australia). Visit the Automic website https://investor. automic.com.au/#/home to register as an ACW shareholder or log in to your existing account. Annual Financial Report 11 Vision and strategy Our fundamentals In conjunction with the  US FDA and other regulatory authorities, we strive for excellence in science and clinical data within our programs. As a result, we’ve conducted multiple high-quality clinical trials to bring our molecule, Xanamem, to this phase 2/3 stage of development. Quality Valued We are valued and respected by patients, physicians, and industry peers to bring Xanamem’s development forward. Science, data and transparency guide us to bring hope and potentially change the world of cognitive impairment forever. Bold Building on the solid scientific rationale for Xanamem’s action, we are rapidly developing programs in multiple disease areas, with a priority on Alzheimer’s disease and depression. Next-Gen Xanamem is a cutting-edge therapy and world-class product that reduces cortisol (the “stress hormone”) levels in the brain. As a result, it is a catalyst for new approaches in managing neurodegenerative and other illnesses. Our Vision Actinogen is advancing a revolutionary oral therapeutic, Xanamem, through pivotal trials to transform treatment for Alzheimer’s disease and major depressive disorder. Our vision is to improve lives by targeting brain cortisol with precision and innovation. Actinogen Medical Limited 12 FY2026 Strategic priorities Accelerate clinical development of Xanamem in Alzheimer’s disease • Meet with FDA and EMA to define the most efficient path to approval • Enrolment of 220 participants with mild to moderate disease in the pivotal XanaMIA trial • Perform an interim safety and efficacy futility analysis in January CY2026 • Efficient prescreening in XanaMIA to identify people with progressive disease using elevated blood pTau181 • Implement an extension trial in which all XanaMIA participants can receive active Xanamem • Ensure high quality rating training and standardization to minimize noise in key efficacy endpoints • Leverage ‘hands on’ clinical operations and management model in Australia and the US to optimize quality and reduce cost Commercial readiness to prepare the market for Xanamem & support future partnerships • Strengthen AD advisory board and elicit updated program guidance • Engage with a broad range of key opinion leaders and principal investigators in AD • Communicate Xanamem’s novel mechanism of action and its differentiated therapeutic profile via multiple channels • Refine Xanamem target product profile in AD based on feedback from market research and AD experts Scaled up manufacturing and related patent protection • Production of a large batch of Xanamem tablets by Catalent, US • Manufacture of an additional 15 kg of API by Asymchem, China • National phase entry for three manufacturing patents Proactively engage with prospective development and commercial partners • Identify and partner with one or more synergistic regional biopharma companies • Continue to develop relationships with potential, future large-cap partners • Review detailed Xanamem data with selected parties under confidentiality agreements • Attend key international and national scientific and business meetings • Form collaborative relationships with all major global regulatory authorities Annual Financial Report 13 14 Actinogen Medical Limited Operating & financial review 1. PRINCIPAL ACTIVITIES The principal activity of the company during the year focused on the ongoing clinical development of Xanamem, a unique inhibitor of the 11β-HSD1 enzyme that achieves target engagement in the brain. It is an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Brain cortisol is associated with a number of neurological diseases, including neurodegenerative diseases such as Alzheimer’s Disease (AD), neuropsychiatric diseases such as major depressive disorder (MDD), and Fragile X syndrome (FXS). 2. OPERATIONS REVIEW Highlights – Accelerating toward pivotal trial results in Alzheimer’s disease: Advanced two major clinical trial programs: • XanaMIA phase 2b/3 AD clinical trial passed 100th participant milestone. Interim analysis scheduled for January 2026 and final results expected Q4 2026 • Completed XanaCIDD phase 2a MDD trial – using the data to support development in Alzheimer’s disease pending independent funding for additional MDD trials. World Health Organization (WHO) granted new and unique International Nonproprietary Name (INN) ‘emestedastat’ to Xanamem Successfully conducted a Type C regulatory meeting on major depressive disorder (MDD) with the US Food & Drug Administration (FDA) Conducted commercial readiness planning in all other major aspects of the business including appointing an experienced Chief Commercial Officer (CCO) to manage commercialization activities, conducting partnering meetings & discussions, protecting intellectual property (IP), conducting regulatory meetings, initiating the clinical pharmacokinetic trial and other ancillary studies Published an academic manuscript in peer-reviewed journal, Clinical Pharmacology in Drug Development Completed production of a 15kg scale-up batch of drug substance from contract manufacturer, Asymchem, which will be manufactured in the US into Xanamem tablets for use in the current and future trials, and confirm readiness for future commercial quantity production Completed an $11.1m capital-raising, received a $9.0 million Research & Development (R&D) tax incentive rebate and established a $13.8m non-dilutive R&D tax incentive funding facility. Funding secured to mid-late CY2026 Delivered another in the series of ’plain English’ Clinical Trials Science Forum (CTSF) neuroscience webinars with the subject title: The critical importance of preparing for commercialization CEO, CMO and CCO presented at numerous significant international conferences and conducted meetings at industry gatherings to continue evaluating potential value-add regional and global business development opportunities. The Company’s 2025 financial year was marked by robust clinical pipeline progress and several major milestones and events including planning for the approaching commercialization of Xanamem. XanaMIA phase 2b/3 AD clinical trial passes 100th participant milestone. Interim analysis scheduled for January 2026 and final results expected Q4 2026 • The pivotal XanaMIA phase 2b/3 AD trial is enrolling 220 participants with elevated levels of the blood biomarker pTau181, designed to identify participants with biomarker-positive AD whose disease is likely to progress during the 36-week treatment period of the tri